GlassScriptPhysician profile
Jennifer Dorn
NPI 1376105171
$2,221.25
in general payments reported to CMS, 2019-2025
27 companies · $438 in 2025
The $438 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $997 · 2022: $266 · 2023: $313 · 2024: $207 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $277.91 | 2021-2025 | |
| Abbvie INC. | $255.90 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $223.07 | 2021-2023 | |
| Glaxosmithkline, LLC. | $179.60 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $178.98 | 2021-2024 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $164.92 | 2021-2025 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $117.53 | 2021-2025 | Spravato |
| Astellas Pharma US INC | $115.31 | 2021-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $83.71 | 2021-2025 | Airsupra, Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $72.74 | 2022 | |
| Novo Nordisk INC | $68.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $62.44 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $54.13 | 2021-2025 | Vaxneuvance, Rotateq, Enflonsia |
| Dexcom, INC. | $50.05 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.11 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $41.52 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $28.43 | 2021 | |
| Tactile Systems Technology INC | $26.79 | 2025 | Nimbl, Flexitouch Plus |
| Mannkind Corporation | $25.06 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $23.56 | 2021 | |
| Medtronic, INC. | $21.95 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.54 | 2022 | |
| Exact Sciences Corporation | $19.28 | 2023 | Cologuard Collection Kit |
| Nevro Corp. | $16.68 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.31 | 2023 | Quviviq |
| Eisai INC. | $15.15 | 2021 | |
| Sanofi Pasteur INC. | $14.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Dorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.